On August 15, 2022, Boston Scientific Corporation announced the acquisition of Obsidio, Inc., a privately-held company that has developed the Gel Embolic Material (GEM) technology used for embolization of blood vessels in the peripheral vasculature. Specific terms of the transaction have not been disclosed.
Wilson Sonsini Goodrich & Rosati represented Obsidio in the transaction. The team includes:
M&A
Jason Breen
Stephanie Chen
David Adler
Jonathan Brecher
Technology Transactions
Ian Edvalson
Kexi Wang
Rachel Slyker
Employee Benefits & Compensation
Scott McCall
Jessica Bliss
Privacy and Cybersecurity
Matt Staples
Daniel Chen
Diya Jajal
Dantam Le
Corporate
Mahnaz Dodge
Employment Litigation
Rebecca Stuart
Alison Renner
Sarah Eller
FDA Regulatory
David Hoffmeister
Eva Yin
For more information, please see the press release.